Ascendis Pharma A/S (NASDAQ:ASND) PT Raised to $140.00 at Morgan Stanley

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its target price lifted by equities research analysts at Morgan Stanley from $116.00 to $140.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has an "equal weight" rating on the biotechnology company's stock. Morgan Stanley's price objective would suggest a potential upside of 14.01% from the company's previous close.

A number of other brokerages also recently commented on ASND. JPMorgan Chase & Co. lifted their price target on shares of Ascendis Pharma A/S from $167.00 to $170.00 and gave the stock an "overweight" rating in a report on Friday, May 3rd. Citigroup lifted their price objective on Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a "buy" rating in a research report on Thursday, February 8th. Cantor Fitzgerald reiterated an "overweight" rating and set a $173.00 target price on shares of Ascendis Pharma A/S in a research report on Wednesday. Wedbush lifted their price target on Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an "outperform" rating in a report on Thursday, February 8th. Finally, StockNews.com lowered shares of Ascendis Pharma A/S from a "hold" rating to a "sell" rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $176.88.

Ascendis Pharma A/S Stock Down 1.0 %

Shares of Ascendis Pharma A/S stock traded down $1.24 during trading on Thursday, hitting $122.80. 503,754 shares of the company were exchanged, compared to its average volume of 382,181. The firm has a 50 day moving average price of $143.60 and a 200 day moving average price of $130.20. The stock has a market capitalization of $7.15 billion, a price-to-earnings ratio of -12.79 and a beta of 0.54. Ascendis Pharma A/S has a fifty-two week low of $83.75 and a fifty-two week high of $161.00.

Institutional Investors Weigh In On Ascendis Pharma A/S

Institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC acquired a new stake in Ascendis Pharma A/S during the 4th quarter valued at $25,000. Private Ocean LLC acquired a new stake in Ascendis Pharma A/S during the 1st quarter valued at approximately $36,000. Quadrant Capital Group LLC raised its position in shares of Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company's stock valued at $42,000 after buying an additional 91 shares during the last quarter. Finally, Signaturefd LLC increased its stake in shares of Ascendis Pharma A/S by 31.9% in the third quarter. Signaturefd LLC now owns 798 shares of the biotechnology company's stock worth $75,000 after buying an additional 193 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.